VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci169039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Jessica M Phan und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Myositis, Inclusion Body, Proteostasis, Valosin Containing Protein. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NIH.
Abstract (Originalsprache)
Pathogenic variants in valosin-containing protein ( VCP ) cause multisystem proteinopathy (MSP), a disease characterized by multiple clinical phenotypes including inclusion body myopathy, Paget’s disease of the bone, and frontotemporal dementia (FTD). How such diverse phenotypes are driven by pathogenic VCP variants is not known. We found that these diseases exhibit a common pathologic feature: ubiquitinated intranuclear inclusions affecting myocytes, osteoclasts, and neurons. Moreover, knock-in cell lines harboring MSP variants show a reduction in nuclear VCP. Given that MSP is associated with neuronal intranuclear inclusions comprised of TDP-43 protein, we developed a cellular model whereby proteostatic stress results in the formation of insoluble intranuclear TDP-43 aggregates. Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP primarily by increasing D2 ATPase activity, where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate. Our findings suggest that VCP function is important for nuclear protein homeostasis, that impaired nuclear proteostasis may contribute to MSP, and that VCP activation may be a potential therapeutic by virtue of enhancing the clearance of intranuclear protein aggregates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- NIH
- NIA
Zitieren
APA
Phan, J. M., Creekmore, B. C., Nguyen, A. T., Bershadskaya, D. D., Darwich, N. F., Mann, C. N., & Lee, E. B. (2024). VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models. Journal of Clinical Investigation. https://doi.org/10.1172/jci169039
Vancouver
Phan JM, Creekmore BC, Nguyen AT, Bershadskaya DD, Darwich NF, Mann CN, et al. VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models. Journal of Clinical Investigation. 2024. doi:10.1172/jci169039
BibTeX
@article{Phan2024,
author = {Phan, Jessica M and Creekmore, Benjamin C and Nguyen, Aivi T and Bershadskaya, Darya D and Darwich, Nabil F and Mann, Carolyn N and Lee, Edward B},
title = {VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci169039}
}
EUVIMED